Federal Circuit Denies En Banc Review of Norvasc Decision
Executive Summary
The pharmaceutical and biotech industries were dealt a blow when the Federal Circuit U.S. Court of Appeals decided not to reconsider its ruling that Pfizer's Norvasc (amlodipine besylate) patent is obvious
You may also be interested in...
Drug Formulations May Be Deemed Obvious More Often Under PTO Guidelines
Patent examiners will have greater freedom to reject a patent application on the grounds that an invention was "obvious to try" under new examination guidelines developed by the Patent and Trademark Office
Drug Formulations May Be Deemed Obvious More Often Under PTO Guidelines
Patent examiners will have greater freedom to reject a patent application on the grounds that an invention was "obvious to try" under new examination guidelines developed by the Patent and Trademark Office
Apotex Is Appealing Plavix Patent Ruling, Links Case to Norvasc
Apotex contends that Plavix is an obvious invention in the same way Norvasc is, but a district court judge made a sharp distinction between the two drugs in ruling that Apotex had failed to prove the patent covering Plavix is invalid or unenforceable